 Immunic NASDAQ: IMUX stock is plummeting on Friday after the company reported a high placebo rate in a Phase 1b clinical trial. This trial is currently ongoing and is testing the effectiveness of IMU-935 in patients with moderate-to-severe psoriasis. 